nebivolol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 1887 118457-14-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nebivolol
  • nebivolol hydrochloride
  • vasoxen
  • bystolic
  • nebivolol HCl
A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.
  • Molecular weight: 405.44
  • Formula: C22H25F2NO4
  • CLOGP: 3.50
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 70.95
  • ALOGS: -4
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 17, 2007 FDA FOREST LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 195.98 11.09 433 29126 253435 53066072
Bradycardia 189.89 11.09 215 29344 70841 53248666
Hyponatraemia 145.84 11.09 235 29324 108372 53211135
Hypertensive crisis 118.92 11.09 83 29476 14423 53305084
Hypotension 95.11 11.09 333 29226 253743 53065764
Drug interaction 95.00 11.09 302 29257 219027 53100480
Rheumatoid arthritis 91.84 11.09 30 29529 314501 53005006
Anaemia 68.51 11.09 319 29240 276399 53043108
Joint swelling 57.67 11.09 29 29530 234609 53084898
Lip oedema 56.00 11.09 31 29528 3576 53315931
Acute motor-sensory axonal neuropathy 54.58 11.09 16 29543 339 53319168
Pain 52.60 11.09 160 29399 588238 52731269
Systemic lupus erythematosus 51.40 11.09 5 29554 125409 53194098
Traumatic coma 50.86 11.09 11 29548 61 53319446
Syncope 50.02 11.09 156 29403 111837 53207670
Fall 49.63 11.09 354 29205 358086 52961421
Treatment failure 47.98 11.09 7 29552 128396 53191111
Rhabdomyolysis 46.97 11.09 86 29473 43837 53275670
Synovitis 45.02 11.09 4 29555 107889 53211618
Hepatocellular injury 44.49 11.09 68 29491 29918 53289589
Hyperkalaemia 43.30 11.09 94 29465 54162 53265345
Drug ineffective 41.72 11.09 274 29285 816971 52502536
Ischaemic stroke 40.62 11.09 50 29509 17943 53301564
Maternal exposure during pregnancy 40.11 11.09 18 29541 155621 53163886
Cardiac failure 39.64 11.09 121 29438 85723 53233784
General physical health deterioration 38.95 11.09 173 29386 146769 53172738
Arthropathy 37.02 11.09 16 29543 141437 53178070
Product prescribing error 36.69 11.09 54 29505 22977 53296530
Glossodynia 36.26 11.09 6 29553 100285 53219222
Angina pectoris 35.57 11.09 60 29499 28665 53290842
Hypokalaemia 35.55 11.09 126 29433 96391 53223116
Atrial fibrillation 35.49 11.09 139 29420 111513 53207994
Melaena 34.96 11.09 60 29499 29069 53290438
Dyspnoea 33.48 11.09 482 29077 585750 52733757
Therapeutic product effect decreased 33.22 11.09 14 29545 125641 53193866
Cerebellar ataxia 32.88 11.09 14 29545 907 53318600
Vertigo 31.66 11.09 85 29474 55996 53263511
Contraindicated product administered 31.48 11.09 18 29541 135611 53183896
Exposure during pregnancy 31.30 11.09 15 29544 124845 53194662
Drug hypersensitivity 27.44 11.09 67 29492 265175 53054332
Hypomagnesaemia 27.05 11.09 49 29510 24762 53294745
Swelling 26.06 11.09 41 29518 191064 53128443
Miosis 25.47 11.09 25 29534 6977 53312530
Arrhythmia 25.20 11.09 60 29499 36719 53282788
Tongue oedema 25.08 11.09 20 29539 4247 53315260
Asthenia 24.77 11.09 295 29264 343295 52976212
Hypertension 24.66 11.09 211 29348 225220 53094287
Disorientation 24.62 11.09 62 29497 39297 53280210
Erythrosis 24.29 11.09 6 29553 64 53319443
Primary hyperaldosteronism 24.12 11.09 6 29553 66 53319441
Infusion related reaction 23.68 11.09 31 29528 155926 53163581
Cholestasis 23.21 11.09 50 29509 28645 53290862
Arthralgia 23.05 11.09 146 29413 439637 52879870
Chronic pigmented purpura 22.79 11.09 6 29553 84 53319423
Presyncope 22.76 11.09 47 29512 26147 53293360
Abdominal discomfort 22.73 11.09 56 29503 221006 53098501
Retroperitoneal haematoma 22.53 11.09 16 29543 2854 53316653
Sopor 22.17 11.09 41 29518 21043 53298464
Resting tremor 21.86 11.09 10 29549 769 53318738
International normalised ratio increased 21.73 11.09 67 29492 47694 53271813
Systemic infection 21.72 11.09 14 29545 2131 53317376
Infection 21.58 11.09 39 29520 172166 53147341
Walking disability 21.20 11.09 12 29547 1445 53318062
Renin decreased 21.03 11.09 6 29553 115 53319392
Rectal haemorrhage 20.58 11.09 60 29499 41421 53278086
Rash 20.00 11.09 155 29404 446036 52873471
Haematoma muscle 19.81 11.09 9 29550 681 53318826
Hypersensitivity pneumonitis 19.43 11.09 14 29545 2556 53316951
Sprue-like enteropathy 19.29 11.09 8 29551 485 53319022
Drop attacks 19.08 11.09 9 29550 742 53318765
Orthostatic hypotension 18.74 11.09 47 29512 29706 53289801
Oedema peripheral 18.74 11.09 160 29399 170627 53148880
Adenocarcinoma metastatic 18.67 11.09 5 29554 75 53319432
Arterial spasm 18.67 11.09 5 29554 75 53319432
Blood aldosterone increased 18.49 11.09 6 29553 180 53319327
Angioedema 18.20 11.09 58 29501 42018 53277489
Hemiparesis 18.03 11.09 38 29521 21437 53298070
Aeromonas infection 17.87 11.09 5 29554 89 53319418
Lactic acidosis 17.64 11.09 53 29506 37200 53282307
Cerebral haematoma 17.58 11.09 15 29544 3499 53316008
Face oedema 17.21 11.09 36 29523 20204 53299303
Peripheral ischaemia 17.14 11.09 17 29542 4802 53314705
Hypoosmolar state 17.09 11.09 6 29553 230 53319277
Urine output increased 17.07 11.09 10 29549 1284 53318223
Death 16.99 11.09 122 29437 357110 52962397
Haematoma 16.83 11.09 49 29510 33795 53285712
Cerebral salt-wasting syndrome 16.81 11.09 4 29555 36 53319471
Hypoglycaemia 16.78 11.09 71 29488 58942 53260565
Agranulocytosis 16.54 11.09 39 29520 23710 53295797
Drug intolerance 16.12 11.09 59 29500 205434 53114073
Microcytic anaemia 16.02 11.09 14 29545 3371 53316136
Product measured potency issue 15.94 11.09 5 29554 134 53319373
Sinus arrhythmia 15.55 11.09 10 29549 1517 53317990
Nocturia 15.27 11.09 20 29539 7630 53311877
Dry gangrene 15.14 11.09 7 29552 552 53318955
Blood pressure increased 15.08 11.09 131 29428 140348 53179159
Platelet disorder 14.94 11.09 10 29549 1621 53317886
Diffuse large B-cell lymphoma stage II 14.94 11.09 4 29555 60 53319447
Peripheral artery stenosis 14.69 11.09 7 29552 591 53318916
Nasopharyngitis 14.57 11.09 56 29503 192239 53127268
Blood loss anaemia 14.50 11.09 21 29538 8802 53310705
Nasal mucosal erosion 14.47 11.09 4 29555 68 53319439
Erysipelas 14.44 11.09 19 29540 7282 53312225
Product use issue 13.84 11.09 36 29523 139548 53179959
Elephantiasis 13.82 11.09 3 29556 17 53319490
Metabolic acidosis 13.74 11.09 53 29506 42189 53277318
Thrombocytopenia 13.68 11.09 127 29432 138600 53180907
Sinus bradycardia 13.64 11.09 27 29532 14574 53304933
Drug abuse 13.63 11.09 72 29487 65454 53254053
Vascular encephalopathy 13.27 11.09 6 29553 449 53319058
Electrolyte imbalance 13.14 11.09 31 29528 18853 53300654
Atrioventricular block complete 13.06 11.09 19 29540 7996 53311511
Intraventricular haemorrhage 13.03 11.09 10 29549 2008 53317499
Renal failure 13.00 11.09 111 29448 118341 53201166
Pericarditis 12.98 11.09 10 29549 64396 53255111
Anuria 12.84 11.09 24 29535 12416 53307091
Disease progression 12.83 11.09 23 29536 101897 53217610
Hyperammonaemia 12.75 11.09 15 29544 5134 53314373
Diarrhoea 12.72 11.09 444 29115 625102 52694405
Loss of personal independence in daily activities 12.65 11.09 12 29547 69803 53249704
Diaphragmatic disorder 12.40 11.09 6 29553 524 53318983
Intra-abdominal haematoma 12.33 11.09 9 29550 1676 53317831
Ductal adenocarcinoma of pancreas 12.23 11.09 4 29555 123 53319384
Inappropriate antidiuretic hormone secretion 12.03 11.09 26 29533 14925 53304582
Affective disorder 11.87 11.09 15 29544 5524 53313983
Prescription drug used without a prescription 11.82 11.09 9 29550 1785 53317722
Hypovolaemic shock 11.75 11.09 15 29544 5582 53313925
Dysarthria 11.68 11.09 49 29510 40519 53278988
Impaired healing 11.67 11.09 11 29548 64194 53255313
Discomfort 11.61 11.09 22 29537 95450 53224057
Action tremor 11.61 11.09 5 29554 333 53319174
Withdrawal hypertension 11.58 11.09 4 29555 146 53319361
Sinusitis 11.57 11.09 51 29508 168513 53150994
Jaundice 11.52 11.09 40 29519 30273 53289234
Hypersensitivity 11.49 11.09 69 29490 210596 53108911
Haemorrhagic stroke 11.41 11.09 15 29544 5743 53313764
Bacterial pyelonephritis 11.38 11.09 5 29554 350 53319157
Musculoskeletal stiffness 11.35 11.09 33 29526 123335 53196172
Epistaxis 11.34 11.09 71 29488 68639 53250868
Pancreatitis acute 11.30 11.09 36 29523 26073 53293434
Psychotic behaviour 11.27 11.09 6 29553 641 53318866
Shock haemorrhagic 11.13 11.09 19 29540 9164 53310343

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 129.76 11.50 496 23795 292972 32196263
Hyperkalaemia 117.52 11.50 197 24094 69553 32419682
Bradycardia 91.09 11.50 179 24112 71383 32417852
Lactic acidosis 77.94 11.50 110 24181 33426 32455809
Hypokalaemia 46.51 11.50 117 24174 54977 32434258
Hypoparathyroidism 44.78 11.50 16 24275 475 32488760
Death 43.50 11.50 144 24147 382373 32106862
Toxicity to various agents 39.40 11.50 45 24246 177996 32311239
Syncope 37.62 11.50 150 24141 89974 32399261
Hypotension 37.02 11.50 282 24009 215828 32273407
Hypertensive crisis 35.20 11.50 38 24253 8779 32480456
Renal artery thrombosis 35.05 11.50 12 24279 313 32488922
Cerebral haematoma 33.09 11.50 28 24263 4783 32484452
Cardiac failure 30.88 11.50 143 24148 91530 32397705
Burnout syndrome 30.71 11.50 9 24282 139 32489096
Presyncope 30.59 11.50 50 24241 17251 32471984
Shock haemorrhagic 29.41 11.50 38 24253 10607 32478628
Product monitoring error 28.77 11.50 20 24271 2554 32486681
Cerebellar ischaemia 27.76 11.50 8 24283 116 32489119
Labelled drug-drug interaction medication error 27.76 11.50 40 24251 12373 32476862
Coma 27.47 11.50 82 24209 42530 32446705
Ischaemic stroke 27.38 11.50 48 24243 17528 32471707
Cerebellar syndrome 26.99 11.50 18 24273 2148 32487087
Melaena 26.54 11.50 71 24220 34594 32454641
Pemphigoid 26.31 11.50 32 24259 8404 32480831
Febrile neutropenia 25.59 11.50 31 24260 119535 32369700
Blood lactic acid 25.45 11.50 10 24281 388 32488847
Vertigo 25.29 11.50 56 24235 24227 32465008
Renal failure 24.98 11.50 179 24112 134299 32354936
White blood cell count decreased 24.92 11.50 19 24272 91179 32398056
Coma uraemic 23.63 11.50 6 24285 52 32489183
Vascular purpura 23.62 11.50 15 24276 1647 32487588
Vitamin B12 decreased 23.55 11.50 13 24278 1103 32488132
Cardiac failure chronic 23.46 11.50 28 24263 7212 32482023
Cholestasis 23.41 11.50 58 24233 26975 32462260
Intercapillary glomerulosclerosis 23.33 11.50 6 24285 55 32489180
Brief psychotic disorder with marked stressors 23.25 11.50 8 24283 212 32489023
Hypertension 23.11 11.50 173 24118 131577 32357658
Angina pectoris 22.70 11.50 63 24228 31363 32457872
Cutaneous lupus erythematosus 22.58 11.50 11 24280 720 32488515
Renal impairment neonatal 22.23 11.50 5 24286 24 32489211
Platelet count decreased 22.18 11.50 32 24259 114559 32374676
Angioimmunoblastic T-cell lymphoma 22.14 11.50 9 24282 382 32488853
Renal ischaemia 21.69 11.50 10 24281 578 32488657
Antibody test abnormal 21.53 11.50 7 24284 155 32489080
Laryngeal cancer metastatic 21.50 11.50 6 24285 77 32489158
Anaemia 21.35 11.50 258 24033 223366 32265869
Orthostatic hypotension 21.13 11.50 54 24237 25596 32463639
Hepatic function abnormal 21.02 11.50 4 24287 44836 32444399
Drug interaction 20.95 11.50 252 24039 217933 32271302
Decreased ventricular preload 20.39 11.50 5 24286 37 32489198
Hepatocellular injury 19.52 11.50 52 24239 25266 32463969
Extrasystoles 19.39 11.50 19 24272 3918 32485317
Enzyme induction 19.33 11.50 5 24286 47 32489188
Bronchitis bacterial 19.10 11.50 10 24281 763 32488472
Agoraphobia 18.01 11.50 7 24284 264 32488971
Left ventricle outflow tract obstruction 17.80 11.50 6 24285 149 32489086
Carbohydrate metabolism disorder 17.65 11.50 4 24287 20 32489215
Infective exacerbation of chronic obstructive airways disease 17.52 11.50 13 24278 1838 32487397
Neurosis 17.44 11.50 6 24285 159 32489076
Potentiating drug interaction 17.27 11.50 20 24271 4988 32484247
Haematoma 17.09 11.50 50 24241 25634 32463601
Hypertensive nephropathy 17.03 11.50 8 24283 483 32488752
Transient ischaemic attack 16.96 11.50 50 24241 25744 32463491
Oral lichen planus 16.80 11.50 6 24285 178 32489057
Interstitial lung disease 16.69 11.50 94 24197 64907 32424328
Retinal disorder 16.59 11.50 10 24281 1001 32488234
Bundle branch block left 16.54 11.50 21 24270 5758 32483477
Electrocardiogram QT prolonged 16.53 11.50 66 24225 39575 32449660
Pain 16.51 11.50 78 24213 187478 32301757
Anticoagulation drug level increased 16.46 11.50 8 24283 521 32488714
Cranial sutures widening 16.45 11.50 5 24286 88 32489147
Dialysis device insertion 16.38 11.50 4 24287 29 32489206
Tooth avulsion 16.38 11.50 4 24287 29 32489206
Diabetic nephropathy 15.75 11.50 13 24278 2146 32487089
Metabolic alkalosis 15.56 11.50 11 24280 1443 32487792
Neutrophil count decreased 15.38 11.50 8 24283 47131 32442104
Electrocardiogram T wave abnormal 15.37 11.50 11 24280 1471 32487764
Perioral dermatitis 15.36 11.50 5 24286 111 32489124
Albumin urine present 15.19 11.50 7 24284 404 32488831
Blood creatine phosphokinase MB increased 14.62 11.50 12 24279 1965 32487270
Congenital inguinal hernia 14.58 11.50 5 24286 131 32489104
Haemorrhagic erosive gastritis 14.55 11.50 5 24286 132 32489103
Brain natriuretic peptide increased 14.54 11.50 17 24274 4283 32484952
Traumatic haemothorax 14.49 11.50 6 24285 267 32488968
Blood loss anaemia 14.06 11.50 23 24268 7939 32481296
Neonatal anuria 13.69 11.50 4 24287 61 32489174
Sinus bradycardia 13.65 11.50 30 24261 12908 32476327
Atrial tachycardia 13.61 11.50 12 24279 2165 32487070
Funguria 13.52 11.50 4 24287 64 32489171
Haemoglobinaemia 13.24 11.50 5 24286 174 32489061
Acute coronary syndrome 13.24 11.50 31 24260 13910 32475325
Cardioactive drug level decreased 13.24 11.50 4 24287 69 32489166
Carcinogenicity 13.18 11.50 4 24287 70 32489165
Glomerulonephritis membranous 13.07 11.50 9 24282 1132 32488103
Oligohydramnios 13.06 11.50 6 24285 344 32488891
Gingival discomfort 12.78 11.50 4 24287 78 32489157
Persistent foetal circulation 12.77 11.50 6 24285 362 32488873
Palpitations 12.75 11.50 57 24234 35912 32453323
Weight decreased 12.71 11.50 183 24108 164635 32324600
Conjunctival haemorrhage 12.63 11.50 13 24278 2842 32486393
Sepsis 12.31 11.50 69 24222 158765 32330470
Arterial stenosis 12.23 11.50 9 24282 1256 32487979
Creatinine urine increased 12.05 11.50 5 24286 224 32489011
IIIrd nerve disorder 11.92 11.50 4 24287 98 32489137
Acute pulmonary oedema 11.87 11.50 21 24270 7720 32481515
Pancreatitis acute 11.79 11.50 46 24245 27289 32461946
Normocytic anaemia 11.79 11.50 11 24280 2136 32487099
Eczema 11.78 11.50 31 24260 14949 32474286
Bone marrow failure 11.78 11.50 4 24287 30400 32458835

Pharmacologic Action:

SourceCodeDescription
ATC C07AB12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, selective
ATC C07BB12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, selective, and thiazides
ATC C07FB12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents and calcium channel blockers
ATC C09DX05 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058665 Adrenergic beta-1 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35530 beta-adrenoceptor antagonists
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:176497 anti-aging drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Angina pectoris off-label use 194828000
Myocardial Reinfarction Prevention off-label use
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Sick sinus syndrome contraindication 36083008 DOID:13884
Bradycardia contraindication 48867003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Cardiogenic shock contraindication 89138009
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Peripheral vascular disease contraindication 400047006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.87 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 5MG BASE;80MG BYVALSON ALLERGAN N206302 June 3, 2016 DISCN TABLET ORAL 7838552 Oct. 4, 2027 METHOD OF TREATING HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 8.50 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 7.50 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 8 WOMBAT-PK
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 5.66 IUPHAR

External reference:

IDSource
4027169 VUID
N0000179202 NUI
D05127 KEGG_DRUG
152520-56-4 SECONDARY_CAS_RN
4027169 VANDF
C0068475 UMLSCUI
CHEBI:64022 CHEBI
CHEMBL434394 ChEMBL_ID
CHEMBL1201731 ChEMBL_ID
D000068577 MESH_DESCRIPTOR_UI
DB04861 DRUGBANK_ID
71301 PUBCHEM_CID
7246 IUPHAR_LIGAND_ID
5969 INN_ID
030Y90569U UNII
236883 RXNORM
130026 MMSL
18486 MMSL
29969 MMSL
52690 MMSL
d05265 MMSL
007077 NDDF
007078 NDDF
318638009 SNOMEDCT_US
395808005 SNOMEDCT_US
734565001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1402 TABLET 2.50 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1405 TABLET 5 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1410 TABLET 10 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 0456-1420 TABLET 20 mg ORAL NDA 26 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7189 TABLET 5 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7190 TABLET 10 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7225 TABLET 2.50 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7226 TABLET 20 mg ORAL ANDA 24 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-353 TABLET 2.50 mg ORAL ANDA 23 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-354 TABLET 5 mg ORAL ANDA 23 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-355 TABLET 10 mg ORAL ANDA 23 sections
nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 13668-356 TABLET 20 mg ORAL ANDA 23 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 31722-585 TABLET 2.50 mg ORAL ANDA 24 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 31722-586 TABLET 5 mg ORAL ANDA 24 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 31722-587 TABLET 10 mg ORAL ANDA 24 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 31722-588 TABLET 20 mg ORAL ANDA 24 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 50090-1127 TABLET 5 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 50090-1307 TABLET 10 mg ORAL NDA 26 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 50090-3326 TABLET 20 mg ORAL NDA 26 sections
Nebivolol Human Prescription Drug Label 1 50090-5708 TABLET 2.50 mg ORAL ANDA 24 sections
Nebivolol Human Prescription Drug Label 1 50090-5752 TABLET 5 mg ORAL ANDA 24 sections
Nebivolol Human Prescription Drug Label 1 50090-5761 TABLET 10 mg ORAL ANDA 24 sections
Nebivolol Human Prescription Drug Label 1 50090-5775 TABLET 20 mg ORAL ANDA 24 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-483 TABLET 2.50 mg ORAL ANDA 25 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-484 TABLET 5 mg ORAL ANDA 25 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-485 TABLET 10 mg ORAL ANDA 25 sections
Nebivolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-486 TABLET 20 mg ORAL ANDA 25 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 54868-5944 TABLET 5 mg ORAL NDA 28 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 54868-6018 TABLET 10 mg ORAL NDA 28 sections
Bystolic HUMAN PRESCRIPTION DRUG LABEL 1 55154-4621 TABLET 5 mg ORAL NDA 25 sections